BioMS MBP8298 positive review
Posted: Thu Oct 27, 2005 10:19 am
Good news for MBP8298 Phase II/III trial...
Data Safety Monitoring Board gives positive review for BioMS Medical's pivotal MS trial
October 27 - CNW - BioMS Medical Corp., a leading developer in the treatment of multiple sclerosis (MS), announced that following the second meeting of its independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. This second recommendation by the DSMB members was based on their recent review of the safety data from patients who have been dosed in the pivotal phase II/III clinical study.
"This recommendation represents solid and steady progress of our lead drug candidate MBP8298," said Kevin Giese, President of BioMS Medical. "MBP8298 is indeed the most advanced drug candidate in clinical testing for secondary progressive MS. Accordingly, we are pleased with the safety profile obtained in patients up to this point."
This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The pivotal phase II/III study is now ongoing at trial sites across Canada, the U.K. and Sweden.
About BioMS Medical Corp.
BioMS Medical Corp. is a biotechnology company dedicated to the development and commercialization of innovative therapies. BioMS Medical's lead drug, MBP8298, is a patented technology for the treatment of multiple sclerosis and is currently in a pivotal Phase II/III clinical trial. The Company is poised to initiate a Phase I clinical trial for HYC750, a therapeutic designed to mobilize stem cells and neutrophils for the treatment of cancer therapy related side-effects. BioMS also has an equity interest in BioCyDex, a private company developing technology for the delivery of drugs into cells.
http://biz.yahoo.com/cnw/051027/bioms_m ... .html?.v=1
Data Safety Monitoring Board gives positive review for BioMS Medical's pivotal MS trial
October 27 - CNW - BioMS Medical Corp., a leading developer in the treatment of multiple sclerosis (MS), announced that following the second meeting of its independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. This second recommendation by the DSMB members was based on their recent review of the safety data from patients who have been dosed in the pivotal phase II/III clinical study.
"This recommendation represents solid and steady progress of our lead drug candidate MBP8298," said Kevin Giese, President of BioMS Medical. "MBP8298 is indeed the most advanced drug candidate in clinical testing for secondary progressive MS. Accordingly, we are pleased with the safety profile obtained in patients up to this point."
This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The pivotal phase II/III study is now ongoing at trial sites across Canada, the U.K. and Sweden.
About BioMS Medical Corp.
BioMS Medical Corp. is a biotechnology company dedicated to the development and commercialization of innovative therapies. BioMS Medical's lead drug, MBP8298, is a patented technology for the treatment of multiple sclerosis and is currently in a pivotal Phase II/III clinical trial. The Company is poised to initiate a Phase I clinical trial for HYC750, a therapeutic designed to mobilize stem cells and neutrophils for the treatment of cancer therapy related side-effects. BioMS also has an equity interest in BioCyDex, a private company developing technology for the delivery of drugs into cells.
http://biz.yahoo.com/cnw/051027/bioms_m ... .html?.v=1